Resistance to PD1/PDL1 checkpoint inhibition - PubMed (original) (raw)
Review
Resistance to PD1/PDL1 checkpoint inhibition
Jake S O'Donnell et al. Cancer Treat Rev. 2017 Jan.
Abstract
For the first time in decades, patients with difficult-to-treat cancers such as advanced stage metastatic melanoma are being offered a glimpse of hope in the form of immunotherapies. By targeting factors that foster the development and maintenance of an immunosuppressive microenvironment within tumors, these therapies release the brakes on the host's own immune system; allowing cure of disease. Indeed, phase III clinical trials have revealed that therapies such as ipilimumab and pembrolizumab which target the CTLA4 and PD-1 immune checkpoints, respectively, have raised the three-year survival of patients with melanoma to ∼70%, and overall survival (>5years) to ∼30%. Despite this unprecedented efficacy, many patients fail to respond, and more concerning, some patients who demonstrate encouraging initial responses to immunotherapy, can acquire resistance over time. There is now an urgent need to identify mechanisms of resistance, to predict outcome and to identify targets for combination therapy. Here, with the aim of guiding future combination trials that target specific resistance mechanisms to immunotherapies, we have summarised and discussed the current understanding of mechanisms promoting resistance to anti-PD1/PDL1 therapies, and how combination strategies which target these pathways might yield better outcomes for patients.
Keywords: Anti-PD1; Checkpoint; Combination therapies; Immunotherapy; Resistance.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
- [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L, Carmier D, Heuzé-Vourc'h N, Diot P, Pichon E. Guilleminault L, et al. Rev Pneumol Clin. 2015 Feb;71(1):44-56. doi: 10.1016/j.pneumo.2014.11.004. Epub 2015 Feb 14. Rev Pneumol Clin. 2015. PMID: 25687821 Review. French. - Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM, Rennert PD, Freeman GJ. Mahoney KM, et al. Nat Rev Drug Discov. 2015 Aug;14(8):561-84. doi: 10.1038/nrd4591. Nat Rev Drug Discov. 2015. PMID: 26228759 Review. - Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK, Atkins M. Philips GK, et al. Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Int Immunol. 2015. PMID: 25323844 Review. - Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Shrimali RK, et al. Immunotherapy. 2015;7(7):777-92. doi: 10.2217/imt.15.49. Epub 2015 Aug 7. Immunotherapy. 2015. PMID: 26250412 Review. - Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O, Carvajal RD. Hamid O, et al. Expert Opin Biol Ther. 2013 Jun;13(6):847-61. doi: 10.1517/14712598.2013.770836. Epub 2013 Feb 19. Expert Opin Biol Ther. 2013. PMID: 23421934 Review.
Cited by
- Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.
Li Q, Geng S, Luo H, Wang W, Mo YQ, Luo Q, Wang L, Song GB, Sheng JP, Xu B. Li Q, et al. Signal Transduct Target Ther. 2024 Oct 7;9(1):266. doi: 10.1038/s41392-024-01953-7. Signal Transduct Target Ther. 2024. PMID: 39370455 Free PMC article. Review. - Single-cell RNA sequencing analysis reveals the distinct features of colorectal cancer with or without Fusobacterium nucleatum infection in PD-L1 blockade therapy.
Ding T, Chen Q, Liu H, Zhang H, Sun Y, Zhao L, Gao Y, Wei Q. Ding T, et al. Heliyon. 2024 Sep 6;10(18):e37511. doi: 10.1016/j.heliyon.2024.e37511. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39309908 Free PMC article. - Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: New promising strategy to reinvigorate cancer therapy.
Hashemi M, Mohandesi Khosroshahi E, Tanha M, Khoushab S, Bizhanpour A, Azizi F, Mohammadzadeh M, Matinahmadi A, Khazaei Koohpar Z, Asadi S, Taheri H, Khorrami R, Ramezani Farani M, Rashidi M, Rezaei M, Fattah E, Taheriazam A, Entezari M. Hashemi M, et al. Heliyon. 2024 Sep 3;10(18):e37376. doi: 10.1016/j.heliyon.2024.e37376. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39309904 Free PMC article. Review. - Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment.
Birnboim-Perach R, Benhar I. Birnboim-Perach R, et al. Int J Biol Sci. 2024 Jul 15;20(10):3911-3922. doi: 10.7150/ijbs.93697. eCollection 2024. Int J Biol Sci. 2024. PMID: 39113705 Free PMC article. Review. - Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy.
Cao X, Hu Z, Sheng X, Sun Z, Yang L, Shu H, Liu X, Yan G, Zhang L, Liu C, Zhang Y, Wang H, Lu H. Cao X, et al. Acta Biochim Biophys Sin (Shanghai). 2024 Jun 28;56(8):1099-1107. doi: 10.3724/abbs.2024110. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38952341 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials